2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3241

Genetic Variation and Tobacco Smoke Exposure in Systemic Lupus Erythematosus: A Case Control Study Among African Americans
Abstract Number: 3242

Identification and Functional Characterization of TNIP1 Causal Variants Associated with Systemic Lupus Erythematosus
Abstract Number: 3243

Intestinal Microbial Dysbiosis in SLE Is Linked to Elevated IgA and Induction of Autoimmunity
Abstract Number: 3244

Observations of Early and Late B Cell Alterations during Belimumab Treatment in Patients with Systemic Lupus Erythematosus Using Mass Cytometry (CyTOF)
Abstract Number: 3245

Surfactant Protein D and Krebs Von Den Lungen-6 Predict Severity of Systemic Sclerosis-Related Interstitial Lung Disease in Two Independent Cohorts
Abstract Number: 3246

Predictors of Long-Term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry
Abstract Number: 3247

Safety and Efficacy of Belimumab with Background Mycophenolate for Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Placebo Controlled, Pilot Trial
Abstract Number: 3248

Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post-Hoc Analyses from the Scleroderma Lung Study I and II
Abstract Number: 3249

Improvement in Cough and Cough-Related Quality of Life in Participants Undergoing Treatment for Systemic Sclerosis-Related Interstitial Lung Disease
Abstract Number: 3250

Serum MCP-1 Levels Predict Long-Term Progression of Interstitial Lung Disease in Systemic Sclerosis
Abstract Number: 3251

Sleep and Physical Activity: A Nationwide Survey Among People with Rheumatic Disease in Ireland
Abstract Number: 3252

Content Analysis of Ergonomic Recommendations Using the Ergonomic Assessment Tool for Arthritis
Abstract Number: 3253

Minimum Physical Function Needed to Walk 6000 Steps/Day in People with Knee Osteoarthritis
Abstract Number: 3254

Use of the Short Valued Life Activities Scale in People with Systemic Sclerosis
Abstract Number: 3255

A Randomized Trial of Automated Telephone-Linked Communication to Improve Exercise Adherence for a Progressive Resistance Training Program in People with Knee Osteoarthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].